{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:15Z","timestamp":1786985415706,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bmc.2022.116760","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T21:31:28Z","timestamp":1650576688000},"page":"116760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants"],"prefix":"10.1016","volume":"64","author":[{"given":"Shangjiu","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.116760_b0005","unstructured":"http:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"10.1016\/j.bmc.2022.116760_b0010","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0140-6736(10)60936-1","article-title":"Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study","volume":"376","author":"Montaner","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2022.116760_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/0003-4819-135-1-200107030-00005","article-title":"Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease","volume":"135","author":"Murphy","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bmc.2022.116760_b0020","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116760_b0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrmicro3490","article-title":"HIV-1 assembly, release and maturation","volume":"13","author":"Freed","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmc.2022.116760_b0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.virol.2015.03.021","article-title":"Retroviral proteases and their roles in virion maturation","volume":"479\u2013480","author":"Konvalinka","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.bmc.2022.116760_b0035","doi-asserted-by":"crossref","unstructured":"Ghosh, A. K.; Dawson, Z. L.; Mitsuya, H. Darunavir, a Conceptually New HIV-1 Protease Inhibitor for the Treatment of Drug-Resistant HIV. Bioorg. Med. Chem. 2007, 15 (24), 7576\u22127580.","DOI":"10.1016\/j.bmc.2007.09.010"},{"key":"10.1016\/j.bmc.2022.116760_b0040","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1021\/acs.jmedchem.7b00172","article-title":"Design and development of highly potent HIV-1 protease inhibitors with a crown-like oxotricyclic core as the P2-ligand to combat multidrug-resistant HIV variants","volume":"60","author":"Ghosh","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116760_b0045","doi-asserted-by":"crossref","first-page":"e02425","DOI":"10.1128\/mBio.02425-17","article-title":"Mechanism of darunavir (DRV)'s high genetic barrier to HIV-1 resistance: a key V32I substitution in protease rarely occurs, but once it occurs, it predisposes HIV-1 to develop DRV resistance","volume":"9","author":"Aoki","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.bmc.2022.116760_b0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/AAC.00909-07","article-title":"Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir","volume":"52","author":"Lambert-Niclot","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2022.116760_b0055","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1073\/pnas.1102278108","article-title":"Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors","volume":"108","author":"Louis","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmc.2022.116760_b0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbrc.2019.08.126","article-title":"Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20","volume":"519","author":"Kneller","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2022.116760_b0065","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/anie.201102762","article-title":"Enhancing protein backbone binding\u2013a fruitful concept for combating drug-resistant HIV","volume":"51","author":"Ghosh","year":"2012","journal-title":"Angew Chem In Ed"},{"key":"10.1016\/j.bmc.2022.116760_b0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/ar7001232","article-title":"Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance","volume":"41","author":"Ghosh","year":"2008","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2022.116760_b0075","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1021\/acs.jmedchem.8b00298","article-title":"Design and synthesis of highly potent HIV-1 protease inhibitors containing tricyclic fused ring systems as novel P2 ligands: structure-activity studies, biological and X-ray structural analysis","volume":"61","author":"Ghosh","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116760_b0080","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1021\/acs.jmedchem.0c00202","article-title":"Structure-based design of highly potent HIV-1 protease inhibitors containing new tricyclic ring P2-ligands: design, synthesis, biological, and X-ray structural studies","volume":"63","author":"Ghosh","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116760_b0085","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1021\/acsmedchemlett.9b00670","article-title":"Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors with P2-carboxamide functionalities","volume":"11","author":"Ghosh","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2022.116760_b0090","doi-asserted-by":"crossref","first-page":"775","DOI":"10.4155\/fmc-2019-0331","article-title":"Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1\u2032 ligands","volume":"12","author":"Zhu","year":"2020","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2022.116760_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115623","article-title":"Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite","volume":"28","author":"Zhu","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2022.116760_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113450","article-title":"Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants","volume":"220","author":"Zhu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.116760_b0105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/cbdd.12224","article-title":"Prodrugs design based on inter- and intramolecular chemical processes","volume":"82","author":"Karaman","year":"2013","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2022.116760_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113498","article-title":"Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase","volume":"220","author":"Zhu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.116760_b0115","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1021\/jm900303m","article-title":"Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-Ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies","volume":"52","author":"Ghosh","year":"2009","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2022.116760_b0120","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cmdc.200600103","article-title":"Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance","volume":"1","author":"Ghosh","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2022.116760_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111900","article-title":"Rational design and structure-activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase","volume":"186","author":"Zhu","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.bmc.2022.116760_b0130","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/acsmedchemlett.0c00043","article-title":"Novel HIV-1 protease inhibitors with morpholine as the P2 ligand to enhance activity against DRV-resistant variants","volume":"11","author":"Zhu","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2022.116760_b0135","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1126\/science.2106161","article-title":"Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer","volume":"247","author":"Matayoshi","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bmc.2022.116760_b0140","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1021\/jm200649p","article-title":"Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure","volume":"54","author":"Ghosh","year":"2011","journal-title":"J Med Chem"},{"issue":"17","key":"10.1016\/j.bmc.2022.116760_b0145","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.1021\/jm400768f","article-title":"Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies","volume":"56","author":"Ghosh","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116760_b0150","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.antiviral.2008.12.004","article-title":"High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay","volume":"81","author":"Garcia","year":"2009","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmc.2022.116760_b0155","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/325773a0","article-title":"Strategies for antiviral therapy in AIDS","volume":"325","author":"Mitsuya","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2022.116760_b0160","doi-asserted-by":"crossref","DOI":"10.1007\/s12272-013-0153-z","article-title":"Design, synthesis and molecular docking of some new 1,2,4-triazolobenzimidazol-3-yl acetohydrazide derivatives with anti-inflammatory-analgesic activities","volume":"36","author":"Mohammed","year":"2013","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.bmc.2022.116760_b0165","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1016\/j.tet.2014.03.038","article-title":"Structural optimization of cyclic sulfonamide based novel HIV-1 protease inhibitors to picomolar affinities guided by X-ray crystallographic analysis","volume":"70","author":"Ganguly","year":"2014","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmc.2022.116760_b0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmc.2022.116760_b0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A hierarchical approach to all-atom protein loop prediction","volume":"55","author":"Jacobson","year":"2004","journal-title":"Proteins"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622001523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622001523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:17:47Z","timestamp":1760836667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622001523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":35,"alternative-id":["S0968089622001523"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116760","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116760"}}